Pathogenesis & Immunologic Targets is a 1-hour enduring CME activity within the NMOSD Grand Rounds educational series. This session focuses on the immunopathogenesis of neuromyelitis optica spectrum disorder (NMOSD) and the corresponding therapeutic targets used in current and emerging treatment strategies. Faculty review the roles of B cells, T cells, and pathogenic antibodies in disease development and discuss mechanisms of action of FDA-approved therapies. The activity also examines principles of immune tolerance and investigational approaches aimed at selective immune modulation. Through evidence-based discussion, this session is designed to improve clinician competence in understanding immunologic mechanisms and applying this knowledge to therapeutic decision-making in NMOSD.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Address:
- 50 Division Street
Pricing
CME included with membership
| Free CME Activity | Free |
Collected from the provider’s public pages · source
Specialties served/covered
- Clinical Informatics
- Dermatology
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Geriatric Psychiatry
- Gynecologic Oncology
- Health Equity & Inclusion
- Medical Leadership & Administration
- Medical Oncology
- Neonatal-Perinatal Medicine
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Pediatric Neurology
- Sleep Medicine
- Surgical Oncology
- Urological Oncology
- Vascular Neurology
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Urology
- No reviews yet. Be the first to share yours.
- Enduring / On-demand
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedMay 9, 2025
-
Last day to claim creditDec 1, 2026 7 weeks left
